BioNTech SE (BNTX)
86.71
-1.38
(-1.57%)
USD |
NASDAQ |
Apr 25, 16:00
86.91
+0.20
(+0.23%)
Pre-Market: 09:02
BioNTech Cash from Operations (TTM): 5.815B for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 5.815B |
September 30, 2023 | 6.398B |
June 30, 2023 | 9.875B |
March 31, 2023 | 9.046B |
December 31, 2022 | 14.32B |
September 30, 2022 | 12.61B |
June 30, 2022 | 10.04B |
March 31, 2022 | 5.973B |
December 31, 2021 | 1.053B |
Date | Value |
---|---|
September 30, 2021 | 1.576B |
June 30, 2021 | -434.16M |
March 31, 2021 | -330.18M |
December 31, 2020 | -15.42M |
September 30, 2020 | -379.41M |
June 30, 2020 | -203.27M |
March 31, 2020 | -247.12M |
December 31, 2019 | -222.22M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-434.16M
Minimum
Jun 2021
14.32B
Maximum
Dec 2022
4.404B
Average
1.576B
Median
Sep 2021
Cash from Operations (TTM) Benchmarks
Pfizer Inc | 8.70B |
BioVie Inc | -41.11M |
Autolus Therapeutics PLC | -145.59M |
Moderna Inc | -3.118B |
Novavax Inc | -713.97M |